1st peanut al­lergy ther­apy gets FDA panel’s back­ing

The Times of India (New Delhi edition) - - Times Global -

AUS Food and Drug Ad­min­is­tra­tion ad­vi­sory panel rec­om­mended ap­prov­ing the first ther­apy for peanut al­ler­gies, which af­fect over 1.6 mil­lion chil­dren in the US, de­spite rais­ing con­cerns about the risk of se­vere al­ler­gic re­ac­tions it poses to young pa­tients.

The body of in­de­pen­dent ad­vis­ers voted 7-2 in favour of ef­fec­tive­ness and 8-1 back­ing safety of the ther­apy Pal­forzia, de­vel­oped by Aim­mune Ther­a­peu­tics. The ver­dict of the panel is an in­flu­en­tial fac­tor in the agency’s fi­nal de­ci­sion. The FDA is ex­pected to make a de­ci­sion on ap­proval early next year.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.